The xerostomia therapeutics market size was valued at USD 2.13 billion in 2024 and is expected to reach USD 2.87 billion by 2032, growing at a CAGR of 3.82% over the forecast period 2025-2032.
The xerostomia therapeutics market growth is driven by a combination of demographic, clinical, and technological growth drivers. Often associated with aging, drug side effects, chronic conditions including diabetes and Sjögren's syndrome, and cancer treatments including chemotherapy and radiation, Xerostomia, or dry mouth, is a frequent ailment resulting from reduced saliva production.
For instance, the National Institutes of Health estimates that xerostomia affects 10% to 15% of the world's population, thereby highlighting the great demand for suitable therapy approaches.
The xerostomia therapeutics market growth has been driven by government bodies and health organizations. With 18.1 million survivors as of January 2022 and estimates reaching 22.5 million by 2032, the U.S. National Cancer Institute notes, for instance, a consistent increase in cancer survivability.
The U.S. xerostomia therapeutics market has shown a constant increasing trend from USD 0.67 billion in 2024 to USD 0.89 billion by 2032, reflecting a 3.74% CAGR over the forecast period.
The cancer therapies are a major cause of dry mouth, which has directly raised demand for xerostomia remedies. Further widening the at-risk group for xerostomia, the Centers for Disease Control and Prevention (CDC) also notes that 85% of Americans 60 years of age and above use at least one prescription drug. These numbers highlight the need for early diagnosis and intervention, which government-sponsored awareness initiatives and revised healthcare guidelines promote.
Drivers
Polypharmacy and Widespread Use of Prescription Drugs in Elderly Populations Raise Xerostomia Cases
Particularly among older persons who are more prone to be on several prescriptions for chronic diseases, the increasing frequency of xerostomia is closely related to the general use of prescription medications for xerostomia.
For instance, the Centers for Disease Control and Prevention estimates that over 1,110 drugs are known to possibly cause dry mouth, and 50% of all adults in the United States take at least one prescription medication daily.
Medication-induced xerostomia accounted for up to 21% of cases in specialized outpatient clinics and over 95% of the dry mouth burden in residential elderly care, according to a recent clinical investigation. Polypharmacy increases the risk of xerostomia; elderly patients using several xerostomia-inducing drugs show a highly significant decrease in salivary flow rates, as demonstrated in an institutional study with a mean unstimulated salivary flow much lower in those on several medications.
Combining medications such as anticholinergics, antidepressants, antihypertensives, and antineoplastics has a synergistic impact that increases the risk and degree of xerostomia. For instance, over 40% of patients stop anticholinergics used for overactive bladder because of unpleasant dry mouth symptoms; xerostomia in 16.9% to 53.7% of patients can result from these medicines. Apart from affecting oral health and quality of life, this medication-induced xerostomia causes lower compliance with required treatments for the main disorders. The demand for efficient xerostomia drugs and dry mouth treatment will keep increasing as the percentage of old people develops globally, and as expected, 20.7% of India's population will be over 60 by 2050.
Restrain
Side Effects and Restrain Current Treatment Limited Effectiveness Hindering Wider Adoption
Many current xerostomia treatments are linked with unpleasant side effects or provide only brief relief, which might affect patient adherence and satisfaction, even with continuous developments. For instance, certain prescription drugs intended to boost saliva production can have side effects including gastrointestinal discomfort, perspiration, or cardiovascular consequences, which would make them inappropriate for long-term use in particular patient groups.
Furthermore, over-the-counter saliva substitutes and gels sometimes only offer temporary relief from symptoms and may not sufficiently imitate the complicated characteristics of natural saliva, therefore causing ongoing discomfort and dental problems. These restrictions draw attention to the necessity of more efficient and better-tolerated treatment choices. Further complicating the management of xerostomia and generating uncertainty for patients and healthcare providers is the absence of consistent treatment recommendations and clear therapeutic advice. Therefore, the market finds it difficult to embrace current therapies widely, which emphasizes the need for ongoing research and development to solve these flaws and improve patient outcomes.
By Type
With a 58% xerostomia therapy market share, the OTC segment dominated the market and is expected to keep its strong expansion at a considerable CAGR during the forecast period. Easily available to consumers without a prescription, OTC xerostomia treatments cover a wide range of saliva substitutes, moisturizing gels, mouth rinses, pills, and chewing gum. Higher incidence of xerostomia follows from the growing usage of drugs for chronic conditions such as antihypertensives, antidepressants, and anticholinergics.
For example, the annual "April is Sjögren's Awareness Month" of the Sjögren's Foundation was rather important in informing the public and healthcare professionals about xerostomia and its therapy choices in April 2025.
Prescription drug use among older adults is rising according to government statistics; the CDC notes that over 85% of persons 60 years of age and above use at least one prescription medicine, and almost 40% use five or more. This rise precisely matches increased demand for over-the-counter alleviation of symptoms.
Recent advancements in OTC xerostomia treatments center on better formulations, such as pH-balanced mouthwashes and mucin-based gels that almost replicate natural saliva. For example, the combination of remineralizing agents with antibacterial compounds in over-the-counter xerostomia therapies has improved their effectiveness in preserving oral health and avoiding issues, including dental caries and infections.
By Product
Comprising 36% of the market share, the salivary stimulants segment has led the xerostomia therapeutics market in 2024. This leadership is primarily attributed to the segment’s clinical effectiveness and its alignment with the needs of a rapidly growing patient population. Patients with residual salivary gland function, including those with Sjögren's syndrome and those undergoing radiation head and neck cancer therapies, are routinely prescribed salivary stimulants, including pilocarpine and cevimeline.
Patients with autoimmune-related xerostomia have benefited from FDA approval of new formulations, including cevimeline, which targets M3 muscarinic receptors for more selective activation. For instance, Aquoral Oral Spray offers patients looking for alternatives to oral drugs a non-systemic solution able to provide up to six hours of relief.
Over the forecast period, the dentifrices segment is expected to have the fastest compound annual growth rate (CAGR). Rising awareness of oral health, the growing frequency of dental problems linked with xerostomia, and strong public health campaigns all help to drive this growth. By containing moisturizing agents, antibacterial agents, and remineralizing components, dentifrices, including specialty toothpaste and oral gels, are meant to offer both symptomatic relief and preventive treatment. Since 2020, the European Centre for Disease Prevention and Control (ECDC) has recorded a 22% rise in oral health problems among Europe's aging population, which has spurred extensive public campaigns encouraging the use of therapeutic dentifrices.
Withheld 40% of the xerostomia therapeutics market share, North America dominated in 2024. Its modern healthcare system, huge healthcare expenditure, and sizable patient pool resulting from high rates of chronic diseases and cancer survivability fuel this dominance. Strong awareness campaigns, such as those run by the Sjögren's Syndrome Foundation, which supports early diagnosis and patient education, also help the area through favorable reimbursement rules and an increasing patient pool affected by chronic illnesses and oncology-induced xerostomia. Ongoing innovation, regulatory backing, and the integration of novel treatment modalities, including OTC and prescription therapies, are expected to help the U.S. market retain its leadership. This has been much expanded in part by government statistics and projects. The CDC's National Oral Health Program allocated USD 23 million in 2023 to increase underprivileged communities' access to dental hygiene products, including dentifrices, to promote oral health.
The Europe region held a substantial revenue share of the global xerostomia therapeutics industry. Leading nations in the region, Germany, France, and the UK, gain from advanced healthcare systems, robust public health campaigns, and a high frequency of xerostomia-inducing diseases. Regulatory reforms and increasing focus on salivary gland dysfunction have encouraged the use of xerostomia drugs and artificial saliva products, particularly in aging populations. Early diagnosis and the use of specialized products have been underlined in recent government-backed campaigns and revised policies from European health authorities, therefore encouraging market development.
Within the xerostomia therapeutics market, the Asia-Pacific region is predicted to exhibit the fastest CAGR of 4.33% throughout the forecast period. Rising healthcare costs, a fast-aging population, and increased frequency of chronic diseases such as diabetes and cancer that cause xerostomia fuel this growth. Supported by its huge population, improving healthcare infrastructure, and increasing knowledge of xerostomia management techniques, China is the biggest market in Asia-Pacific. The government's emphasis on enhancing oral health results is a major market driver, as is the acceptance of radiation therapy and chemotherapy in cancer treatment. For example, the Ministry of Health of Japan recorded a 17% increase in xerostomia instances connected to polypharmacy among elderly people, which resulted in fresh subsidies for therapeutic dentifrices under public health campaigns.
The major xerostomia therapeutics companies are Parnell Pharmaceuticals, Inc., GlaxoSmithKline plc, Pfizer, Inc., Colgate-Palmolive Company, Pendopharm, Sun Pharmaceuticals Industries Ltd., Lupin Pharmaceuticals, Inc., Church & Dwight Co., Inc., Acacia Pharma, OraCoat, Hikma Pharmaceuticals PLC, and others.
GSK shared positive results from its EAGLE-1 Phase III study in April 2024, therefore underlining the potential of gepotidacin as a novel oral treatment for uncomplicated urogenital gonorrhea, even amid rising drug resistance.
Aimed at treating Grade 2/3 radiation-induced xerostomia, MeiraGTx gained FDA's RMAT designation for AAV2-hAQP1 in December 2024.
| Report Attributes | Details |
|---|---|
| Market Size in 2024 | USD 2.13 Billion |
| Market Size by 2032 | USD 2.87 Billion |
| CAGR | CAGR of 3.82% From 2025 to 2032 |
| Base Year | 2024 |
| Forecast Period | 2025-2032 |
| Historical Data | 2021-2023 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Type (OTC, and Prescription) • By Product (Salivary Substitutes, Salivary Stimulants, and Dentifrices) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) |
| Company Profiles | Parnell Pharmaceuticals, Inc., GlaxoSmithKline plc, Pfizer, Inc., Colgate-Palmolive Company, Pendopharm, Sun Pharmaceuticals Industries Ltd., Lupin Pharmaceuticals, Inc., Church & Dwight Co., Inc., Acacia Pharma, OraCoat, Hikma Pharmaceuticals PLC |
Ans. The projected market size for the Xerostomia therapeutics market is USD 2.87 billion by 2032.
Ans: The North American region dominated the Xerostomia therapeutics market in 2024.
Ans. The CAGR of the Xerostomia therapeutics market is 3.82% during the forecast period of 2025-2032.
Ans: Polypharmacy and widespread use of prescription drugs in elderly populations raise xerostomia cases, driving market growth.
Ans: The Salivary Stimulants segment dominated the Xerostomia therapeutics market.
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.2 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Pharmaceutical Volume – Production & Usage (2024)
5.2 Healthcare Spending – Xerostomia (2024)
5.3 Regulatory & Reimbursement Landscape (2024)
5.4 Therapeutic Pipeline and R&D Activity (2024)
6. Competitive Landscape
6.1 List of Major Companies By Region
6.2 Market Share Analysis By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and Supply Chain Strategies
6.4.3 Expansion Plans and New Product Launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Xerostomia Therapeutics Market Segmentation By Type
7.1 Chapter Overview
7.2 OTC
7.2.1 OTC Trend Analysis (2021-2032)
7.2.2 OTC Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3 Prescription
7.3.1 Prescription Market Trends Analysis (2021-2032)
7.3.2 Prescription Market Size Estimates and Forecasts to 2032 (USD Billion)
8. Xerostomia Therapeutics Market Segmentation By Product
8.1 Chapter Overview
8.2 Salivary Substitutes
8.2.1 Salivary Substitutes Market Trends Analysis (2021-2032)
8.2.2 Salivary Substitutes Market Size Estimates and Forecasts to 2032 (USD Billion)
8.3 Salivary Stimulants
8.3.1 Salivary Stimulants Market Trends Analysis (2021-2032)
8.3.2 Salivary Stimulants Market Size Estimates and Forecasts to 2032 (USD Billion)
8.4 Dentifrices
8.4.1 Dentifrices Market Trends Analysis (2021-2032)
8.4.2 Dentifrices Market Size Estimates and Forecasts to 2032 (USD Billion)
9. Regional Analysis
9.1 Chapter Overview
9.2 North America
9.2.1 Trends Analysis
9.2.2 North America Xerostomia Therapeutics Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
9.2.3 North America Xerostomia Therapeutics Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.2.4 North America Xerostomia Therapeutics Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
9.2.5 USA
9.2.5.1 USA Xerostomia Therapeutics Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.2.5.2 USA Xerostomia Therapeutics Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
9.2.6 Canada
9.2.6.1 Canada Xerostomia Therapeutics Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.2.6.2 Canada Xerostomia Therapeutics Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
9.2.7 Mexico
9.2.7.1 Mexico Xerostomia Therapeutics Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.2.7.2 Mexico Xerostomia Therapeutics Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
9.3 Europe
9.3.1 Trends Analysis
9.3.2 Europe Xerostomia Therapeutics Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
9.3.3 Europe Xerostomia Therapeutics Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.3.4 Europe Xerostomia Therapeutics Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
9.3.5 Germany
9.3.5.1 Germany Xerostomia Therapeutics Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.3.5.2 Germany Xerostomia Therapeutics Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
9.3.6 France
9.3.6.1 France Xerostomia Therapeutics Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.3.6.2 France Xerostomia Therapeutics Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
9.3.7 UK
9.3.7.1 UK Xerostomia Therapeutics Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.3.7.2 UK Xerostomia Therapeutics Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
9.3.8 Italy
9.3.8.1 Italy Xerostomia Therapeutics Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.3.8.2 Italy Xerostomia Therapeutics Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
9.3.9 Spain
9.3.9.1 Spain Xerostomia Therapeutics Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.3.9.2 Spain Xerostomia Therapeutics Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
9.3.10 Poland
9.3.10.1 Poland Xerostomia Therapeutics Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.3.10.2 Poland Xerostomia Therapeutics Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
9.3.11 Turkey
9.3.11.1 Turkey Xerostomia Therapeutics Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.3.11.2 Turkey Xerostomia Therapeutics Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
9.3.12 Rest of Europe
9.3.12.1 Rest of Europe Xerostomia Therapeutics Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.3.12.2 Rest of Europe Xerostomia Therapeutics Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
9.4 Asia Pacific
9.4.1 Trends Analysis
9.4.2 Asia Pacific Xerostomia Therapeutics Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
9.4.3 Asia Pacific Xerostomia Therapeutics Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.4.4 Asia Pacific Xerostomia Therapeutics Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
9.4.5 China
9.4.5.1 China Xerostomia Therapeutics Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.4.5.2 China Xerostomia Therapeutics Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
9.4.6 India
9.4.5.1 India Xerostomia Therapeutics Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.4.5.2 India Xerostomia Therapeutics Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
9.4.5 Japan
9.4.5.1 Japan Xerostomia Therapeutics Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.4.5.2 Japan Xerostomia Therapeutics Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
9.4.6 South Korea
9.4.6.1 South Korea Xerostomia Therapeutics Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.4.6.2 South Korea Xerostomia Therapeutics Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
9.4.7 Singapore
9.4.7.1 Singapore Xerostomia Therapeutics Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.4.7.2 Singapore Xerostomia Therapeutics Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
8.4.8 Australia
8.4.8.1 Australia Xerostomia Therapeutics Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
8.4.8.2 Australia Xerostomia Therapeutics Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
9.4.9 Rest of Asia Pacific
9.4.9.1 Rest of Asia Pacific Xerostomia Therapeutics Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.4.9.2 Rest of Asia Pacific Xerostomia Therapeutics Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
9.5 Middle East & Africa
9.5.1 Trends Analysis
9.5.2 Middle East & Africa Xerostomia Therapeutics Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
9.5.3 Middle East & Africa Xerostomia Therapeutics Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.5.4 Middle East & Africa Xerostomia Therapeutics Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
9.5.5 UAE
9.5.5.1 UAE Xerostomia Therapeutics Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.5.5.2 UAE Xerostomia Therapeutics Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
9.5.6 Saudi Arabia
9.5.6.1 Saudi Arabia Xerostomia Therapeutics Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.5.6.2 Saudi Arabia Xerostomia Therapeutics Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
9.5.7 Qatar
9.5.7.1 Qatar Xerostomia Therapeutics Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.5.7.2 Qatar Xerostomia Therapeutics Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
9.5.8 South Africa
9.5.8.1 South Africa Xerostomia Therapeutics Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.5.8.2 South Africa Xerostomia Therapeutics Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
9.5.9 Middle East & Africa
9.5.9.1 Middle East & Africa Xerostomia Therapeutics Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.5.9.2 Middle East & Africa Xerostomia Therapeutics Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
9.6 Latin America
9.6.1 Trends Analysis
9.6.2 Latin America Xerostomia Therapeutics Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
9.6.3 Latin America Xerostomia Therapeutics Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.6.4 Latin America Xerostomia Therapeutics Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
9.6.5 Brazil
9.6.5.1 Brazil Xerostomia Therapeutics Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.6.5.2 Brazil Xerostomia Therapeutics Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
9.6.6 Argentina
9.6.6.1 Argentina Xerostomia Therapeutics Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.6.6.2 Argentina Xerostomia Therapeutics Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
9.6.7 Rest of Latin America
9.6.7.1 Rest of Latin America Xerostomia Therapeutics Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.6.7.2 Rest of Latin America Xerostomia Therapeutics Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
10. Company Profiles
10.1 Parnell Pharmaceuticals, Inc.
10.1.1 Company Overview
10.1.2 Financial
10.1.3 Product / Services Offered
10.1.4 SWOT Analysis
10.2 GlaxoSmithKline plc
10.2.1 Company Overview
10.2.2 Financial
10.2.3 Product/ Services Offered
10.2.4 SWOT Analysis
10.3 Pfizer, Inc
10.3.1 Company Overview
10.3.2 Financial
10.3.3 Product/ Services Offered
10.3.4 SWOT Analysis
10.4 Colgate-Palmolive Company
10.4.1 Company Overview
10.4.2 Financial
10.4.3 Product/ Services Offered
10.4.4 SWOT Analysis
10.5 Pendopharm
10.5.1 Company Overview
10.5.2 Financial
10.5.3 Product/ Services Offered
10.5.4 SWOT Analysis
10.6 Sun Pharmaceuticals Industries Ltd.
10.6.1 Company Overview
10.6.2 Financial
10.6.3 Product/ Services Offered
10.6.4 SWOT Analysis
10.7 Lupin Pharmaceuticals, Inc.
10.7.1 Company Overview
10.7.2 Financial
10.7.3 Product/ Services Offered
10.7.4 SWOT Analysis
10.8 Church & Dwight Co., Inc.
10.8.1 Company Overview
10.8.2 Financial
10.8.3 Product/ Services Offered
10.8.4 SWOT Analysis
10.9 Acacia Pharma
10.9.1 Company Overview
10.9.2 Financial
10.9.3 Product/ Services Offered
10.9.4 SWOT Analysis
10.10 OraCoat
10.10.1 Company Overview
10.10.2 Financial
10.10.3 Product/ Services Offered
10.10.4 SWOT Analysis
11. Use Cases and Best Practices
12. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
By Type
OTC
Prescription
By Product
Salivary Substitutes
Salivary Stimulants
Dentifrices
Request for Segment Customization as per your Business Requirement: Segment Customization Request
North America
US
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Poland
Turkey
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
UAE
Saudi Arabia
Qatar
South Africa
Rest of Middle East & Africa
Latin America
Brazil
Argentina
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Detailed Volume Analysis
Criss-Cross segment analysis (e.g. Product X Application)
Competitive Product Benchmarking
Geographic Analysis
Additional countries in any of the regions
Customized Data Representation
Detailed analysis and profiling of additional market players
